Innovative Drug Development in Dermatology
Latest News

June 30, 2014

Brickell announces licensing agreement for its novel retinoid therapy, BBI-3000, with Merz North America.
Read Article (PDF)


Focused on the development of novel therapies for the treatment of skin diseases.

Brickell Biotech, Inc. is a clinical-stage pharmaceutical company focused on the development of innovative, first-in-class therapeutics to satisfy current unmet human needs in the global dermatology markets.



Brickell Biotech, Inc. © 2014 All Rights Reserved.